On July 12, 2018, Health Canada had published “Guidance on Notifying Health Canada of Foreign Actions – Guidance Document for Industry”. On November 20, 2018, Health Canada updated its Guidance, including with a link to an on-line reporting form: Notifying Health Canada of Foreign Actions - Guidance Document for Industry, updated November 20, 2018. This update comes after the foreign risk reporting requirement provisions of the Food and Drug Regulations (as previously reported) came into force in October 2018. We have updated our previously published chart to include this Guidance.
Related Publications & Articles
-
Health Canada finalizes biosimilar guidance: comparative clinical efficacy studies not typically required
In Canada, biosimilar products are approved by way of a new drug submission, following Health Canada guidance first released in 2010 and significantly revised in 2016.Read More -
2026 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2026, the Rx IP Update team reported on a number of developments in Canadian life sciences IP and regulatory law. Below are our top storiesRead More -
Supreme Court of Canada: methods of medical treatment unpatentable, validity of Janssen’s paliperidone dosing regimen patent upheld
Today the Supreme Court of Canada released its decision in Pharmascience Inc v Janssen Inc, 2026 SCC 26 on the patentability of methods of medical treatment, dismissing Pharmascience’s appeal.Read More
